Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Brentuximab Vedotin 27pembrolizumab 13Nivolumab 11Dacarbazine 8Vinblastine 7Doxorubicin 7Gemcitabine 6Bendamustine Hydrochloride 6plerixafor 5fludarabine 4Rituximab 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Azacitidine 4abexinostat 3Melphalan 3Filgrastim 3Etoposide 3Busulfan 3Bleomycin 3umbralisib 2relatlimab 2pegfilgrastim 2mocetinostat 2itacitinib 2givinostat hydrochloride 2givinostat 2fludarabine phosphate 2durvalumab 2cc-486 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hodgkin Disease × lucatumumab × Clear all
NCT00670592 2020-12-17

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Novartis

Phase 1/2 Completed
111 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡